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============

Heart failure (HF) affects approximately 6 million adults in the USA, with more than \$30 billion in associated annual costs; by 2030, these figures are expected to rise to more than 8 million adults and more than \$69 billion \[[@CR1]\]. From 2012 to 2014, the age-adjusted rate of HF-related deaths per 100,000 people increased from 81.4 to 84.0 \[[@CR2]\].

Individuals with HF are broadly classified into two groups based on their left ventricular ejection fraction (EF) values: HF with preserved EF (HFpEF) and HF with reduced EF (HFrEF); the prevalence of each is approximately 50% \[[@CR3]\]. The 2013 ACCF/AHA (American College of Cardiology Foundation/American Heart Association) Guideline for the Management of Heart Failure defines HFrEF as HF with an EF ≤ 40% and HFpEF as HF with an EF ≥ 50%, with subcategories of HFpEF borderline (EF 41--49%) and HFpEF improved (EF \> 40% in patients with previous HFrEF) \[[@CR3]\]. Demographics, comorbidities, prognoses, and responses to treatment may differ between HFpEF and HFrEF, leading to distinct treatment and management needs \[[@CR3]\].

Direct medical costs account for more than two-thirds of the total cost for HF, with hospital readmissions substantially driving these costs \[[@CR4], [@CR5]\]. HF was the leading cause of 30-day readmissions for Medicare patients in 2011, costing \$1.75 billion \[[@CR6]\]. To reduce the frequency of readmissions, the Hospital Readmissions Reduction Program of the Centers for Medicare & Medicaid Services (CMS) issued a rule in October 2012 that reduces payments to hospitals with excess 30-day readmission rates for HF (among other conditions) \[[@CR7]\]. Consequently, healthcare providers are increasing their efforts to ensure that patients with HF receive the correct medications and adhere to treatment regimens following discharge \[[@CR8]\]. However, for patients with HF, medication reconciliation can be challenging, mainly because of the complex guidelines for treating HF (and related comorbidities), which can require 6--9 medications at discharge \[[@CR9]--[@CR13]\]. Such complexity may impact medication adherence and introduce the potential for medication errors, both of which may precipitate hospital readmission \[[@CR12], [@CR14]\]. Patients with HF and concomitant comorbidities are particularly vulnerable to rehospitalization \[[@CR15], [@CR16]\].

Gaps in the transition of care (TOC) for patients with HF must be addressed during the peri- and postdischarge periods. These include provider assessment of the patient prior to discharge (failure to recognize worsening status or evaluate/address comorbidities); provision of information to patients and caregivers on the risks of medication errors and adverse drug events (failure to provide adequate patient/caregiver education); handoff communication between the hospital and the primary care provider (PCP), home healthcare team, and patient (lack of or poor communication); and discharge planning (e.g., medication errors, patient lack of adherence to self-care, lack of or poor follow-up care) \[[@CR14]\]. As such, a multidisciplinary team is needed to provide an integrated approach to patient care \[[@CR14], [@CR17]\]. Hospital- and clinic-based pharmacists with advanced training in HF, as well as community pharmacists, are important members of this team. The pharmacist's role in the care of patients with HF includes medication reconciliation and education; medication initiation; dosage titration, adjustment, and monitoring; developing disease management pathways; and posthospital discharge follow-up, clinic, and home visits \[[@CR18]\]. The aim of this article is to review strategies to improve HF TOC using pharmacists (and pharmacist-led interventions) as integral members of the multidisciplinary team. This article does not contain any new studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Pharmacist Participation in TOC for Patients with HF Improves Outcomes {#Sec2}
======================================================================

Numerous studies have shown that community-based pharmacists, as part of multidisciplinary TOC teams, can improve outcomes for patients with HF \[[@CR10], [@CR19]--[@CR25]\]. The impact of pharmacist intervention was evaluated in a pharmacy-led TOC program for patients with HF from a US hospital \[[@CR25]\]. Admission medication reconciliation and discharge medication review were performed to monitor for appropriateness and dosing, duplications, omissions, and drug interactions. Since its initiation, the program has increased compliance with HF core measures (including appropriate medication use) and reduced HF readmissions, 30-day readmissions, all-cause readmissions, and costs \[[@CR25]\]. Similarly, implementation of a care-transition pharmacist in a community hospital to address medication-related issues that contributed to readmissions for patients discharged with diagnoses of chronic obstructive pulmonary disease (COPD) or HF showed that receipt of a follow-up phone call from the care-transition pharmacist within 72 h after discharge led to a significantly lower overall 30-day acute care services use rate of 22% (vs 42% for those who did not receive a phone call; *P* = 0.01) and a 48% lower likelihood of requirement for acute-care services within 30 days of discharge (risk ratio = 0.52; 95% confidence interval \[CI\] 0.33--0.82) \[[@CR26]\].

In 2007, the impact of active pharmacy intervention (i.e., baseline medication history review; patient-centered counseling; monitoring of adherence, healthcare encounters, and body weight; and as-needed communication with other clinicians) compared with usual care (i.e., rotating pharmacists without specialized training distributing patient medication) was investigated in a 9-month randomized study in outpatients with HF \[[@CR22]\]. Intervention significantly improved patient adherence to taking, scheduling, and refilling cardiovascular medications; decreased hospital admissions or emergency department visits; and decreased healthcare utilization and costs \[[@CR22]\]. In the randomized, controlled Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study, the effects of adding a clinical pharmacist to an HF management team providing outpatient clinic service were explored \[[@CR19]\]. Patients who received pharmacist intervention had reduced rates of all-cause mortality and nonfatal HF events (hospitalizations and emergency department visits for HF) compared with patients who received usual follow-up care (4/90 vs 16/91, respectively; odds ratio = 0.22; 95% CI 0.07--0.65; *P* = 0.005). The intervention group was also closer to the optimal angiotensin-converting enzyme inhibitor (ACEI) dosage at 6 months of follow-up compared with the usual-care group (*P* \< 0.001) \[[@CR19]\]. In an assessment of clinical pharmacist intervention in an outpatient HF clinic, pharmacist-provided assistance with HF medication titrations increased the proportion of patients who achieved optimal ACEI, angiotensin receptor blocker (ARB), and β-blocker dosages \[[@CR20]\].

Community pharmacists can also work successfully with hospitals during TOC of patients with HF \[[@CR21]\]. CMS Part D Medication Therapy Management (MTM) programs require prescription drug plan sponsors to optimize medication-related aspects of patient care in collaboration with licensed and practicing pharmacists and physicians; however, pharmacists can bill for counseling patients who have multiple chronic diseases (including HF), take several medications, and pay high costs for their prescriptions \[[@CR27], [@CR28]\]. One recent study found that involving a community pharmacist in MTM services at discharge significantly reduced 30-day hospital readmission rates from 20% to 7% (*P* = 0.017) and improved adherence to medication and self-care \[[@CR21]\]. Similar outcomes were observed when pharmacists individualized medication and disease-state counseling, ensured correct medications at discharge, and provided follow-up reminders and counseling \[[@CR10], [@CR23]\].

Key Factors in HF TOC Managed by Clinical Pharmacists {#Sec3}
=====================================================

Clinical pharmacists are critical team members and are well positioned to be involved in HF TOC in both the inpatient and outpatient settings \[[@CR17]\]. As recommended by the Heart Failure Society of America (HFSA) and American College of Clinical Pharmacy Cardiology Practice and Research Network, clinical pharmacists must routinely identify and resolve common drug-related problems to improve outcomes in patients with HF (Table [1](#Tab1){ref-type="table"}) \[[@CR5]\]. In a pharmacist-led medication reconciliation project, an average of seven medication discrepancies were found per patient with HF during hospitalization and at discharge \[[@CR29]\]. Incorporating pharmacist review as a standard practice during and after hospitalization can identify errors for correction, thereby reducing the risk of adverse drug events \[[@CR30]--[@CR33]\]. In the Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) study, which evaluated an intervention consisting of medication reconciliation at admission and discharge, counseling early in hospitalization and at discharge, and a follow-up call after discharge, medication reconciliation was identified as the most important component of the intervention to improve TOC \[[@CR31]\]. A pooled analysis of two randomized controlled trials assessing the effect of pharmacist intervention in patients with HF or hypertension showed that the risk of adverse drug events and medication errors was reduced by 35% and 37%, respectively, compared with controls (adverse drug events risk ratio 0.65; 95% CI 0.47--0.90; medication errors risk ratio, 0.63; 95% CI 0.40--0.98) \[[@CR32]\].Table 1Common drug-related problems in patients with heart failure.Reprinted from Journal of Cardiac Failure, 19(5), Milfred-LaForest SK et al. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network, 354--369, Copyright (2013), with permission from Elsevier \[[@CR5]\]ProblemPatient indicated for a treatment whoLack of treatmentIs not receiving the treatmentSuboptimal treatmentIs receiving the wrong medicationUndertreatmentIs receiving a subtherapeutic doseInaccessible treatmentIs unable to obtain medicationOverdoseIs receiving a toxic doseAdverse reaction to treatmentIs receiving an indicated dose and experiences treatment-related side effectsDrug interactionIs receiving an indicated dose and experiences side effects due to interactions with other treatments or dietary componentsOff-label useHas no FDA-approved indication for the treatment being used*FDA* Food and Drug Administration

Improper use of medications, including nonsteroidal anti-inflammatory drugs, calcium channel blockers (in patients with HFrEF), and antiarrhythmic agents, can exacerbate HF symptoms and result in hospitalization \[[@CR12]\]. It is important for providers to be aware of medications that are contraindicated in patients with HF (Table [2](#Tab2){ref-type="table"}) and inquire about patient use of complementary and alternative medicine (CAM) and nonprescription therapies \[[@CR34]--[@CR37]\]. One study observed that the rates of CAM use were 31% in women and 12% overall \[[@CR38]\]. Another study found rates of herbal medication and other nonprescription therapies of approximately 20% each and over-the-counter medication use of greater than 75% \[[@CR39]\]. Furthermore, with the approval of novel medications for HF, such as the ARB/neprilysin inhibitor (ARNI) combination therapy, sacubitril/valsartan, and the hyperpolarization-activated cyclic nucleotide-gated channel blocker ivabradine, pharmacists must monitor appropriate use of these with other HF medications \[[@CR40], [@CR41]\]. ARNIs are recommended to reduce morbidity and mortality in patients with chronic HFrEF and to replace ACEIs or ARBs in patients with chronic, symptomatic HFrEF and New York Heart Association (NYHA) class II/III \[[@CR40], [@CR42]\]. Sacubitril/valsartan cannot be used concomitantly in patients taking ACEIs (requires a washout of ≥ 36 h), in people with diabetes taking aliskiren, and in pregnancy \[[@CR40]\]. Ivabradine is recommended to reduce risk of hospitalization in patients with symptomatic (NYHA class II/III), stable, chronic HFrEF (EF \< 35%) who are in sinus rhythm with a resting heart rate of ≥ 70 bpm and receiving guideline-directed evaluation and management (GDEM, including a β-blocker at maximum tolerated dose) \[[@CR41], [@CR42]\]. The use of ivabradine with other negative chronotropes requires monitoring because of an increased risk for bradycardia, and it cannot be used in patients with blood pressure measurements \< 90/50 mmHg, resting heart rates \< 60 bpm, or demand pacemakers set to rates ≥ 60 bpm \[[@CR41]\]. Pharmacists can also educate the healthcare team about new medications and their uses (e.g., recommendations for starting dosages and dose titration), including how to identify which patients should receive them. Recent guideline updates, such as the 2017 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure, provide key information from professional clinical organizations for the appropriate and meaningful incorporation of new agents into routine practice \[[@CR42], [@CR43]\].Table 2Medications contraindicated in patients with heart failure.(Adapted from Amabile 2004 and Page 2016---Source: American Heart Association, Inc) \[[@CR34]--[@CR37]\]Medication/medication classRecommendationPrimary reasons for contraindication/cautionCorticosteroidsConservative use; lowest dosesSodium and fluid retentionNonsteroidal anti-inflammatory drugsAvoid in patients with symptomatic left ventricular dysfunctionSodium and water retention\
Compromise effects of diuretics\
Increase systemic vascular resistanceAntiarrhythmic agents (class I and III, excluding amiodarone)Avoid all class I agents\
Avoid ibutilide and sotalolNegative inotropic activity\
Proarrhythmic effectsAntihypertensive agents α1-antagonistsDo not useCardiac hypertrophy Non-dihydropyridine calcium channel blockersAvoid useNegative inotropic activity\
Neurohormonal activation MinoxidilAvoid useFluid retention\
Stimulation of RAASAntihyperglycemic agents MetforminAvoid use in patients with NYHA class III/IV symptoms and those with previous hospitalization for HF exacerbations; conservative use with monitoring in othersIncreased anaerobic glucose metabolism and lactate elevation Alogliptin and saxagliptinAvoid use in patients who develop signs and symptoms of HF, especially if the patient has CV or renal disease at baselineUnknown ThiazolidinedionesAvoid use in patients with NYHA class III/IV symptoms; monitor for new or increased HF symptoms in othersFluid retentionHematologic medications AnagrelideAvoidPositive inotropic activity\
Tachycardia CilostazolDo not useInhibition of phosphodiesterase IIINeurologic and psychiatric medications AmphetaminesAvoid usePeripheral α- and β-agonist activities\
Tachycardia, arrhythmia CarbamazepineAvoid if possible; use other first-line agentsNegative inotropic and chronotropic effects\
Suppression of sinus nodal automaticity and atrioventricular conduction\
Anticholinergic effects ClozapineActively monitor for new or increased HF symptomsUnknown Ergot alkaloidsAvoid use if possible; if used, monitor regularly for new murmursIncreased serum norepinephrine\
Excess serotonin activity PergolideAvoid use if possibleExcess serotonin levels Tricyclic antidepressantsAvoid if possible; use other first-line agentsNegative inotropic effects\
Increase in automaticity\
Slowing of intracardiac conduction\
ProarrhythmicMiscellaneous medications β~2~-agonistsAvoid long-term systemic administrationDirect positive chronotropic effect\
Hypokalemia Herbal medicationsAvoidUnknown; lack of data for most\
Increased risk of bleeding\
Hypertension\
Sodium retention ItraconazoleAvoidNegative inotropic activity Sulfamethoxazole/trimethoprimAvoid in patients taking an ACEi or ARBRisk of hyperkalemia and sudden death TheophyllineAvoid use in decompensated HFIncreased theophylline levels and toxicity TNF-α inhibitorsAvoid if new-onset or worsening HF symptoms develop; infliximab doses of \> 5 mg/kg contraindicatedCytokine-mediated myocardial toxicity*ACE* angiotensin-converting enzyme, *ARB* angiotensin receptor blocker, *CV* cardiovascular, *HF* heart failure, *NYHA* New York Heart Association, *RAAS* renin--angiotensin--aldosterone system, *TNF-α* tumor necrosis factor alpha

The pharmacy team should consider several factors during the HF TOC: (1) general patient physical assessment; (2) medication regimens and laboratory test results; (3) pharmacotherapeutic management to ensure that patients receive dose-optimized GDEM with limited adverse effects; (4) potential for drug--drug or drug--condition interactions; (5) other medication-related issues, including perceived versus absolute contraindications; and (6) type (or lack) of insurance coverage and out-of-pocket medication costs, and possible less expensive alternatives \[[@CR11], [@CR30], [@CR44], [@CR45]\]. The requirements for MTM programs are generally aligned with these considerations \[[@CR27]\]. Overall, the pharmacist should ensure that all prescribed medications are for approved indications and patients receive clear and practical instructions for dosage and administration, including duration of therapy \[[@CR44]\].

Impact of Pharmacists Counseling Patients During TOC {#Sec4}
====================================================

In the PILL-CVD study, intervention incorporating early initial inpatient pharmacist consultation was found to be useful for obtaining background and baseline information, building relationships, and facilitating discharge counseling \[[@CR31]\]. During an initial consultation, pharmacists can gauge the patient's level of understanding to individualize education and correct misunderstandings \[[@CR29]\]. Discharge counseling can also help patients understand their new medication regimen. In the PILL-CVD study, discharge counseling included reviewing medications, establishing a plan for filling new prescriptions, identifying potential barriers to adherence, provision of adherence aids, and "teach-back" methods to ensure patient understanding \[[@CR31]\]. Pharmacists noted the importance of emphasizing the difference between regimens at admission and postdischarge, particularly when using the same drug at a different dosage \[[@CR31]\].

Face-to-face interactions with pharmacists can be beneficial for inpatients and outpatients and may lead to reduced readmission rates \[[@CR12], [@CR21], [@CR46]--[@CR48]\]. A pooled data analysis from 10 randomized clinical trials showed that HF management programs which provide in-person communication/education reduced hospital readmissions significantly (2.5%; *P* \< 0.001) compared with usual care \[[@CR49]\].

The recently introduced ACC Patient Navigator Program aims to reduce readmission by providing personalized support to patients as they face challenges associated with HF hospitalization and TOC \[[@CR49]\]. The ACC also developed the Hospital to Home Initiative (Fig. [1](#Fig1){ref-type="fig"}) that provides resources to improve TOC and reduce HF readmission rates \[[@CR50]\].Fig. 1Overview of the American College of Cardiology's Hospital to Home (H2H) Project \[[@CR66]\]

Unique Roles of the Pharmacy Team in Improving Patient Health {#Sec5}
=============================================================

Collaborative-care models that include pharmacists have been shown to reduce all-cause and HF-related hospitalizations and to improve overall patient health and satisfaction \[[@CR12], [@CR51]\]. Studies in inpatient settings have shown positive effects of clinical pharmacist collaborations with HF teams, including improving physician adherence to GDEM \[[@CR12], [@CR30], [@CR51]\]. Clinical pharmacists can serve as valuable consultants to providers \[[@CR30]\]. Communication delays can be prevented and recommended drug therapy can be implemented effectively via email communication between clinical pharmacists and providers \[[@CR52]\]. In our experience, attention to comments made by the inpatient team (e.g., pending laboratory testing and follow-up instruction comments) can be especially helpful to ambulatory care pharmacists when developing patient-specific plans and goals.

Similarly, pharmacist collaboration with outpatient HF clinicians can improve medication recommendations, assessments, and education \[[@CR51]\]. Community pharmacists can provide services to facilitate the TOC \[[@CR53]\]. A Scottish study found that cognitive HF services by community pharmacists were well received by patients and improved their understanding of the conditions and medications, medication adherence, and self-care \[[@CR54]\]. Initial consultation reviewed each HF medication (e.g., how and why taken, adherence issues), patient perceptions and understanding of side effects, identification and assessment of HF symptoms, importance of monitoring weight, and smoking status; answered patient questions; and formulated an action plan to resolve any problems, which included referral to other clinicians if needed. Follow-up consultation assessed HF symptom changes, reviewed previously discussed problems and the actions taken to address them, discussed care outcomes, and referred patients to other clinicians if needed \[[@CR54]\]. Team-based care involving a pharmacist is essential to the Agency for Healthcare Research and Quality's patient-centered medical home model \[[@CR55]\].

Strategies to Encourage Adherence {#Sec6}
=================================

The often-complicated HF treatment regimens may compromise adherence, of which pharmacists may promote using various strategies. In a randomized controlled trial that compared 9 months of active pharmacist intervention and 3 months of follow-up assessment with usual care for low-income patients with HF, medication adherence during this timeframe was higher among those who received active intervention compared with patients who did not (78.8%; 95% CI 74.9--82.7 vs 67.9%; 95% CI 63.8--72.1, respectively) \[[@CR22]\].

Adherence is significantly worse among patients with inadequate versus adequate health literacy; however, pharmacist intervention that includes patient education, therapeutic monitoring, and communication with PCPs can substantially improve adherence in these patients \[[@CR56]\]. Techniques such as determining whether the patient comprehends pill-bottle label instructions can encourage adherence \[[@CR31]\]. Available tools that facilitate health literacy assessment throughout the TOC process are listed in Table [3](#Tab3){ref-type="table"} \[[@CR57]--[@CR59]\].Table 3Summary of common health literacy assessment tools \[[@CR57]--[@CR59]\]ToolAdvantagesDisadvantagesREALMCan be administered in \< 3 minDoes not measure understandingRequires minimal trainingEstimates may be more affected by response bias than on S-TOFHLAMost commonly used in clinical settingsContains 66 itemsTOFHLAMeasures health information comprehensionAdministration requires up to 22 minIs used as the gold standard for comparison of new toolsS-TOFHLAMeasures health information comprehensionCategorizes individuals as having "inadequate skills" at almost 2 times the rate of REALM, possibly because it may be less accurate at measuring prior knowledge compared with REALMAdministration requires 7--8 minCommonly used in clinical settingsNVSHas a high sensitivity for detecting limited health literacyBecause of its high sensitivity, it is not as useful as other tests in a research setting, when precision is requiredCan be administered in \< 3 min*NVS* newest vital sign, *REALM* rapid estimate of adult literacy in medicine, *S-TOFHLA* short test of functional health literacy in adults, *TOFHLA* test of functional health literacy in adults

Other predictors of suboptimal adherence of which pharmacists should be aware include nonwhite race, younger age, more-severe HF and comorbidities, depression, smoking status, previous nonadherence, living alone, Medicaid insurance, lack of insurance, and medication regimens that require frequent dosing or disruption of the patient's daily activities \[[@CR13], [@CR60]\]. Addressing adherence issues starts with identifying patients with a history of or risk factors for poor adherence. Pharmacists in the PILL-CVD study reported that the most useful question at initial consultation was how many days the patient missed taking one (or more) of the medications during the week prior to hospitalization, because it helped identify the history, nature, and consequences of nonadherence \[[@CR31]\]. Identification of adherence barriers allows for the initiation of strategies to overcome them, as exemplified by the SIMPLE approach (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR61]\]. Pharmacist interventions, including use of adherence aids, have been shown to substantially improve adherence \[[@CR56]\]. In addition, an illustrated medication schedule can help patients fill their pillboxes correctly \[[@CR31]\].Fig. 2Strategies to improve adherence: the SIMPLE approach \[[@CR61]\]

Strategies to Improve Current Limitations of Treatment Transitions {#Sec7}
==================================================================

Mobile health (mHealth) approaches (e.g., the use of instant messaging or text messaging interventions to communicate with patients) can improve self-care following hospital discharge. HF self-management was improved with an intervention in which patients began receiving text messages regarding medication, dietary, and appointment adherence; HF symptom recognition; health management to address symptoms; and healthcare navigation the day after hospital discharge \[[@CR62]\]. Mobile health tools have been used in patients with cardiovascular disease (CVD) to promote medication adherence, improve weight management, increase physical activity, aid smoking cessation, facilitate self-management of diabetes mellitus, and improve hypertension and dyslipidemia care \[[@CR63]\]. In addition, the AHA has developed a self-check plan for tracking symptoms, a "Questions to Ask Your Doctor" document, and numerous heart health trackers (e.g., activity, blood pressure, and healthcare team trackers) \[[@CR64]\].

Social determinants of health identified as influencing the incidence, treatment, and outcomes of CVD include socioeconomic status, race/ethnicity, social support, culture/language, access to care, and residential environment \[[@CR65]\]; these factors also impact the success of the TOC process. For example, in the text messaging intervention study described above, almost one-quarter of low-income patients did not have access to personal cell phones and most did not have smartphones; thus, such patients are less likely to benefit from mHealth approaches \[[@CR62]\]. It has been suggested that providing low-income patients with cell phones could be cost-effective for improving patient accessibility and outcomes \[[@CR62]\].

Conclusions {#Sec8}
===========

Heart failure is one of the most common and costly diseases in the USA, and the number of HF-related deaths is increasing. Pharmacists are integral to multidisciplinary TOC teams in HF. During the transition from hospital to ambulatory home- or community-based care, pharmacy services (including medication reconciliation, identification and prevention of adverse drug events, suggestions for improving medication access, and patient education) can improve outcomes and decrease the risk for rehospitalization. Cohesive multidisciplinary team approaches can improve medication adherence and provide a trusted resource for patients' questions. Novel technologies and expanded access to pharmacy services can improve current limitations of transitional care in HF and other chronic diseases.
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